Ovagen (20 mg Vial) Dosage Protocol
Quickstart Highlights
Ovagen is a synthetic ultrashort tripeptide (Glu-Asp-Leu; EDL) studied as a bioregulator of gastrointestinal and liver tissues[1]. In vitro studies demonstrate that EDL increases cell proliferation and modulates aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures[2]. No controlled human trials exist; available data are preclinical and cell-based. This educational protocol presents a once-daily subcutaneous approach with gradual titration using microgram-level dosing.
- Reconstitute: Add 2.0 mL bacteriostatic water → 10 mg/mL (10,000 μg/mL) concentration.
- Typical daily range: 10–150 μg once daily (gradual titration over 16 weeks).
- Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 μg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (2 mL = 10 mg/mL)
| Week | Daily Dose (μg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 10 μg (0.01 mg) | 0.1 units (0.001 mL) |
| Weeks 3–4 | 20 μg (0.02 mg) | 0.2 units (0.002 mL) |
| Weeks 5–6 | 50 μg (0.05 mg) | 0.5 units (0.005 mL) |
| Weeks 7–8 | 100 μg (0.1 mg) | 1 unit (0.01 mL) |
| Weeks 9–16 | 100–150 μg (0.1–0.15 mg) | 1–1.5 units (0.01–0.015 mL) |
Frequency: Inject once daily subcutaneously. Because all per-administration volumes are ≤1.5 units (≤0.015 mL), use 30-unit or 50-unit insulin syringes for improved readability and accuracy. Titrate slowly by adding 10–20 μg (0.1–0.2 units) every 1–2 weeks as tolerated[3].
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on a 16-week daily protocol with gradual titration. One 20 mg vial provides approximately 13,510 μg total usage over 16 weeks, so a single vial is sufficient for the full course.
-
Peptide Vials (Ovagen, 20 mg each):
- 16 weeks: 1 vial (with excess remaining)
-
Insulin Syringes (U-100, 30-unit or 50-unit recommended):
- Per week: 7 syringes (1/day)
- 16 weeks: 112 syringes (recommend ~120 with extras)
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 16 weeks (1 vial): 2 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Protocol Overview
Concise summary of the once-daily regimen.
- Goal: Support gastrointestinal and hepatic tissue bioregulation over time[1].
- Schedule: Daily subcutaneous injections for 16 weeks with gradual titration.
- Dose Range: 10–150 μg daily with slow escalation.
- Reconstitution: 2.0 mL per 20 mg vial (10 mg/mL) for precise microgram measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
- Start: 10 μg daily for Weeks 1–2; increase to 20 μg for Weeks 3–4.
- Escalate: 50 μg for Weeks 5–6; then 100 μg for Weeks 7–8.
- Maintenance: 100–150 μg daily for Weeks 9–16.
- Frequency: Once per day (subcutaneous).
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality[4][5].
- Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; for long-term stability, −80 °C (−112 °F) is optimal.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within a few days or aliquot and freeze to minimize hydrolysis.
- Do not store thawed solution longer than 1–2 days at 2–8 °C; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes (30-unit or 50-unit preferred for low-volume accuracy); dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Label the vial with date/time of reconstitution, diluent volume, final concentration, and initials[4].
How This Works
Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis[1][6]. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, suggesting cytoprotective effects[2]. Such ultrashort peptides are known to influence cell differentiation, proliferation, and apoptosis via gene regulation[3]. Additionally, EDL has been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site[7].
Potential Benefits & Side Effects
Observations from preclinical and in vitro literature (no controlled human trials available).
- May support gastrointestinal and hepatic tissue bioregulation based on ultrashort peptide bioregulator research[1].
- In vitro studies indicate potential cytoprotective effects via modulation of aging-related gene expression[2].
- Ultrashort peptides generally exhibit rapid metabolism and low immunogenicity[6].
- Side effects are not well characterized due to lack of human clinical data; mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced diet supporting gastrointestinal and liver health.
- Maintain regular physical activity to support overall metabolic function.
- Prioritize sleep and stress management to support adherence and recovery.
- Avoid excessive alcohol and hepatotoxic substances during the protocol.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8].
- Clean the vial stopper and skin with 60–70% alcohol; allow to dry[8].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid tissue irritation; keep at least ~2 cm between injections on the same area.
- Use a 23–25 gauge needle (5/8″ length) or standard insulin syringe needles (28–31G)[10].
Recommended Source
We recommend Pure Lab Peptides for high-purity Ovagen (20 mg).
Why Pure Lab Peptides?
- High-purity, third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
-
MDPI International Journal of Molecular Sciences
— Transport of biologically active ultrashort peptides using POT and LAT carriers -
PubMed — Advances in Gerontology
— Tripeptides slow down aging process in renal cell culture (Khavinson et al., 2014) -
Nature — Signal Transduction and Targeted Therapy
— Therapeutic peptides: current applications and future directions (Li et al., 2022) -
Sigma-Aldrich
— Peptide Handling and Storage Guide (aliquoting, freeze–thaw, labeling) -
Bachem
— Handling and Storage Guidelines for Peptides (temperature, stability) -
PubMed — Biochemistry
— HIV-1 protease inhibitors: enthalpic versus entropic optimization of binding affinity -
PubMed — Biochemistry
— HIV-1 protease inhibitors Glu-Asp-Leu and Glu-Asp-Phe: thermodynamic studies (Velazquez-Campoy & Freire, 2000) -
NCBI Bookshelf — WHO
— Best practices for injections and related procedures (asepsis, preparation, administration) -
CDC
— Vaccine administration: subcutaneous route (angle/site guidance) -
CDC (Subcut Injection PDF)
— Technique diagram and site guidance for subcutaneous injections -
Pure Lab Peptides
— Ovagen (20 mg) product page (quality and batch documentation)